Recommendation of the President – Veoza (fezolinetant)

On 10 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 143/2024 on the appropriateness of approving the reimbursement of the medicinal product Veoza (fezolinetant) for the indication: treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in patients undergoing prophylactic anti-estrogen hormone therapy based on tamoxifen for pre-invasive breast cancer

Publication in Public Information Bulletin (BIP) >>